卡介苗不良反应临床处理指南

2021-06-01 中华医学会结核病学分会 中国防痨杂志,2021,43(6): 532-538.

卡介苗(bacillus Calmette-Guérin,BCG)是一种预防结核病的减毒活疫苗,是至今全球接种最广泛、最安全的疫苗之一。中国自1978年开始广泛接种BCG后,儿童粟粒性结

中文标题:

卡介苗不良反应临床处理指南

发布日期:

2021-06-01

简要介绍:

卡介苗(bacillus Calmette-Guérin,BCG)是一种预防结核病的减毒活疫苗,是至今全球接种最广泛、最安全的疫苗之一。中国自1978年开始广泛接种BCG后,儿童粟粒性结核病及结核性脑膜炎的发病率和死亡率显著降低。除了应用于预防结核病外,BCG也常用于膀胱原位癌灌注治疗,采用BCG灌注可以降低和延缓非肌层浸润性膀胱癌的复发和进展,是目前公认效果最佳的膀胱灌注药品。但是由于生产工艺、疫苗毒力强弱、疫苗使用方法及个体差异等因素,BCG接种及灌注后的不良反应也时有发生。目前,BCG不良反应的临床处理尚未统一和规范。为此,中华医学会结核病学分会联合中国防痨协会学校与儿童结核病防治专业分会,组织专家进行深入讨论,制定了《卡介苗不良反应临床处理指南》。本指南介绍了BCG种类、使用方法,以及BCG不良反应的表现、诊断、治疗及预防等,以期医护人员用于规范处理BCG不良反应。

 

相关资料下载:
[AttachmentFileName(sort=1, fileName=卡介苗不良反应临床处理指南_卢水华.pdf)] GetToolGuiderByIdResponse(projectId=1, id=755d61c00211a489, title=卡介苗不良反应临床处理指南, enTitle=, guiderFrom=中国防痨杂志,2021,43(6): 532-538., authorId=0, author=, summary=卡介苗(bacillus Calmette-Gu&eacute;rin,BCG)是一种预防结核病的减毒活疫苗,是至今全球接种最广泛、最安全的疫苗之一。中国自1978年开始广泛接种BCG后,儿童粟粒性结, cover=https://img.medsci.cn/2021623/1624435730958_2020535.jpg, journalId=0, articlesId=null, associationId=715, associationName=中华医学会结核病学分会, associationIntro=null, copyright=0, guiderPublishedTime=Tue Jun 01 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>卡介苗(bacillus Calmette-Gu&eacute;rin,BCG)是一种预防结核病的减毒活疫苗,是至今全球接种最广泛、最安全的疫苗之一。中国自1978年开始广泛接种BCG后,儿童粟粒性结核病及结核性脑膜炎的发病率和死亡率显著降低。除了应用于预防结核病外,BCG也常用于膀胱原位癌灌注治疗,采用BCG灌注可以降低和延缓非肌层浸润性膀胱癌的复发和进展,是目前公认效果最佳的膀胱灌注药品。但是由于生产工艺、疫苗毒力强弱、疫苗使用方法及个体差异等因素,BCG接种及灌注后的不良反应也时有发生。目前,BCG不良反应的临床处理尚未统一和规范。为此,中华医学会结核病学分会联合中国防痨协会学校与儿童结核病防治专业分会,组织专家进行深入讨论,制定了《卡介苗不良反应临床处理指南》。本指南介绍了BCG种类、使用方法,以及BCG不良反应的表现、诊断、治疗及预防等,以期医护人员用于规范处理BCG不良反应。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=4279, tagName=卡介苗)], categoryList=[CategoryDto(categoryId=35, categoryName=预防与公卫, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=4279, guiderKeyword=卡介苗, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2112, appHits=64, showAppHits=0, pcHits=535, showPcHits=2048, likes=0, shares=8, comments=5, approvalStatus=1, publishedTime=Wed Jun 23 17:23:35 CST 2021, publishedTimeString=2021-06-01, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Wed Jun 23 16:09:00 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 20:12:38 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=卡介苗不良反应临床处理指南_卢水华.pdf)])
卡介苗不良反应临床处理指南_卢水华.pdf
下载请点击:
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1075442, encodeId=d33a10e5442ca, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03a94799581, createdName=75505628, createdTime=Tue Nov 30 14:53:56 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057993, encodeId=9771105e99348, content=收藏学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bb85598371, createdName=henghengbobo, createdTime=Wed Oct 06 00:30:43 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057895, encodeId=1740105e89507, content=卡介苗不良反应在学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210629/43ee537f00864dc6b68ccbc86ebea3b3/be6937cd68114645938c23cea58469c7.jpg, createdBy=da7f5520374, createdName=ms4000001913410108, createdTime=Tue Oct 05 15:03:02 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055840, encodeId=786d105584014, content=不断学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210629/43ee537f00864dc6b68ccbc86ebea3b3/be6937cd68114645938c23cea58469c7.jpg, createdBy=da7f5520374, createdName=ms4000001913410108, createdTime=Tue Sep 28 22:17:49 CST 2021, time=2021-09-28, status=1, ipAttribution=)]
    2021-11-30 75505628

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1075442, encodeId=d33a10e5442ca, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03a94799581, createdName=75505628, createdTime=Tue Nov 30 14:53:56 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057993, encodeId=9771105e99348, content=收藏学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bb85598371, createdName=henghengbobo, createdTime=Wed Oct 06 00:30:43 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057895, encodeId=1740105e89507, content=卡介苗不良反应在学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210629/43ee537f00864dc6b68ccbc86ebea3b3/be6937cd68114645938c23cea58469c7.jpg, createdBy=da7f5520374, createdName=ms4000001913410108, createdTime=Tue Oct 05 15:03:02 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055840, encodeId=786d105584014, content=不断学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210629/43ee537f00864dc6b68ccbc86ebea3b3/be6937cd68114645938c23cea58469c7.jpg, createdBy=da7f5520374, createdName=ms4000001913410108, createdTime=Tue Sep 28 22:17:49 CST 2021, time=2021-09-28, status=1, ipAttribution=)]
    2021-10-06 henghengbobo

    收藏学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1075442, encodeId=d33a10e5442ca, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03a94799581, createdName=75505628, createdTime=Tue Nov 30 14:53:56 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057993, encodeId=9771105e99348, content=收藏学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bb85598371, createdName=henghengbobo, createdTime=Wed Oct 06 00:30:43 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057895, encodeId=1740105e89507, content=卡介苗不良反应在学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210629/43ee537f00864dc6b68ccbc86ebea3b3/be6937cd68114645938c23cea58469c7.jpg, createdBy=da7f5520374, createdName=ms4000001913410108, createdTime=Tue Oct 05 15:03:02 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055840, encodeId=786d105584014, content=不断学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210629/43ee537f00864dc6b68ccbc86ebea3b3/be6937cd68114645938c23cea58469c7.jpg, createdBy=da7f5520374, createdName=ms4000001913410108, createdTime=Tue Sep 28 22:17:49 CST 2021, time=2021-09-28, status=1, ipAttribution=)]
    2021-10-05 ms4000001913410108

    卡介苗不良反应在学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1075442, encodeId=d33a10e5442ca, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03a94799581, createdName=75505628, createdTime=Tue Nov 30 14:53:56 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057993, encodeId=9771105e99348, content=收藏学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bb85598371, createdName=henghengbobo, createdTime=Wed Oct 06 00:30:43 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057895, encodeId=1740105e89507, content=卡介苗不良反应在学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210629/43ee537f00864dc6b68ccbc86ebea3b3/be6937cd68114645938c23cea58469c7.jpg, createdBy=da7f5520374, createdName=ms4000001913410108, createdTime=Tue Oct 05 15:03:02 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055840, encodeId=786d105584014, content=不断学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210629/43ee537f00864dc6b68ccbc86ebea3b3/be6937cd68114645938c23cea58469c7.jpg, createdBy=da7f5520374, createdName=ms4000001913410108, createdTime=Tue Sep 28 22:17:49 CST 2021, time=2021-09-28, status=1, ipAttribution=)]
    2021-09-28 ms4000001913410108

    不断学习

    0

拓展阅读

2018 WHO意见书:卡介苗

世界卫生组织(WHO,The World Health Organization) · 2018-02-23